Search
Allist Receives Approval for Clinical Trial of Fumetinib for New Indication
2025-01-17 /
Read about 0 minute
Author：小编
Allist recently announced the receipt of an "Approval Notice for Drug Clinical Trial" from the National Medical Products Administration. The company's self-developed Fumetinib Tablets (Fumetinib) have been granted approval to proceed with clinical research for a new indication. This study is targeted at patients with stage IB-IIIB non-small cell lung cancer who possess non-classical mutations in the epidermal growth factor receptor and have undergone radical resection. The objective of the study is to assess the efficacy and safety of Fumetinib as an adjuvant therapy, in comparison to a placebo.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
